155 related articles for article (PubMed ID: 31791649)
21. Immune Checkpoint Inhibitors and Beyond: An Overview of Immune-Based Therapies in Merkel Cell Carcinoma.
Samimi M
Am J Clin Dermatol; 2019 Jun; 20(3):391-407. PubMed ID: 30784027
[TBL] [Abstract][Full Text] [Related]
22. Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer.
Hoffner B; Leighl NB; Davies M
Cancer Treat Rev; 2020 Apr; 85():101979. PubMed ID: 32078962
[TBL] [Abstract][Full Text] [Related]
23. Appearance of New Cutaneous Superficial Basal Cell Carcinomas during Successful Nivolumab Treatment of Refractory Metastatic Disease: Implications for Immunotherapy in Early Versus Late Disease.
Cohen PR; Kato S; Goodman AM; Ikeda S; Kurzrock R
Int J Mol Sci; 2017 Jul; 18(8):. PubMed ID: 28788102
[TBL] [Abstract][Full Text] [Related]
24. Immunotherapy Advances in Urothelial Carcinoma.
Jain RK; Snyders T; Nandagopal L; Garje R; Zakharia Y; Gupta S
Curr Treat Options Oncol; 2018 Dec; 19(12):79. PubMed ID: 30554335
[TBL] [Abstract][Full Text] [Related]
25. Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions.
Tripathi A; Plimack ER
Curr Urol Rep; 2018 Nov; 19(12):109. PubMed ID: 30406502
[TBL] [Abstract][Full Text] [Related]
26. Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
Zhang Y; Zhou H; Zhang L
J Immunother Cancer; 2018 Dec; 6(1):135. PubMed ID: 30509312
[TBL] [Abstract][Full Text] [Related]
27. Patterns of immunotherapy use and management of toxicities in regional and tertiary settings.
Hamilton B; Xu K; Honeyball F; Balakrishnar B; Zielinski R
Intern Med J; 2019 Aug; 49(8):1010-1015. PubMed ID: 30693623
[TBL] [Abstract][Full Text] [Related]
28. Anti-programmed cell death protein 1 (anti-PD1) immunotherapy induced autoimmune polyendocrine syndrome type II (APS-2): a case report and review of the literature.
Gunjur A; Klein O; Kee D; Cebon J
J Immunother Cancer; 2019 Sep; 7(1):241. PubMed ID: 31488221
[TBL] [Abstract][Full Text] [Related]
29. [Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers].
Duruisseaux M; Rouquette I; Adam J; Cortot A; Cazes A; Gibault L; Damotte D; Lantuejoul S
Ann Pathol; 2017 Feb; 37(1):61-78. PubMed ID: 28162296
[TBL] [Abstract][Full Text] [Related]
30. New perspectives in Merkel cell carcinoma.
Del Marmol V; Lebbé C
Curr Opin Oncol; 2019 Mar; 31(2):72-83. PubMed ID: 30694842
[TBL] [Abstract][Full Text] [Related]
31. Peripheral Blood TCR Repertoire Profiling May Facilitate Patient Stratification for Immunotherapy against Melanoma.
Hogan SA; Courtier A; Cheng PF; Jaberg-Bentele NF; Goldinger SM; Manuel M; Perez S; Plantier N; Mouret JF; Nguyen-Kim TDL; Raaijmakers MIG; Kvistborg P; Pasqual N; Haanen JBAG; Dummer R; Levesque MP
Cancer Immunol Res; 2019 Jan; 7(1):77-85. PubMed ID: 30425105
[TBL] [Abstract][Full Text] [Related]
32. Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series.
Naqash AR; File DM; Ziemer CM; Whang YE; Landman P; Googe PB; Collichio FA
J Immunother Cancer; 2019 Jan; 7(1):4. PubMed ID: 30621779
[TBL] [Abstract][Full Text] [Related]
33. Anti-PD-1 immunotherapy in combination with sequential involved-site radiotherapy in heavily pretreated refractory Hodgkin lymphoma.
Quéro L; Gilardin L; Fumagalli I; Martin V; Guillerm S; Bauduceau O; Kirova YM; Hennequin C; Brice P
Cancer Radiother; 2019 Apr; 23(2):132-137. PubMed ID: 30733172
[TBL] [Abstract][Full Text] [Related]
34. Remarkable Alteration of PD-L1 Expression after Immune Checkpoint Therapy in Patients with Non-Small-Cell Lung Cancer: Two Autopsy Case Reports.
Takahashi T; Tateishi A; Bychkov A; Fukuoka J
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31130676
[TBL] [Abstract][Full Text] [Related]
35. Complete responses to two different anti-PD1 agents in a metastatic melanoma patient.
Kilickap S; Guven DC; Aktepe OH; Aktas BY; Dizdar O
J Oncol Pharm Pract; 2020 Mar; 26(2):496-499. PubMed ID: 31256744
[TBL] [Abstract][Full Text] [Related]
36. [Two cases of granuloma annulare under anti-PD1 therapy].
Charollais R; Aubin F; Roche-Kubler B; Puzenat E
Ann Dermatol Venereol; 2018 Feb; 145(2):116-119. PubMed ID: 29221649
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma.
Kreft S; Gesierich A; Eigentler T; Franklin C; Valpione S; Ugurel S; Utikal J; Haferkamp S; Blank C; Larkin J; Garbe C; Schadendorf D; Lorigan P; Schilling B
Eur J Cancer; 2019 Jul; 116():207-215. PubMed ID: 31212163
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma.
Longoria TC; Tewari KS
Expert Opin Drug Metab Toxicol; 2016 Oct; 12(10):1247-53. PubMed ID: 27485741
[TBL] [Abstract][Full Text] [Related]
39. Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810.
Falchook GS; Leidner R; Stankevich E; Piening B; Bifulco C; Lowy I; Fury MG
J Immunother Cancer; 2016; 4():70. PubMed ID: 27879972
[TBL] [Abstract][Full Text] [Related]
40. Pseudoprogression on treatment with immune-checkpoint inhibitors in patients with gastrointestinal malignancies: Case series and short literature review.
Michalarea V; Fontana E; Garces AI; Williams A; Smyth EC; Picchia S; Rao S; Chau I; Cunningham D; Bali MA
Curr Probl Cancer; 2019 Oct; 43(5):487-494. PubMed ID: 30827742
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
